Related Experiment Video
Updated: Apr 4, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
11.3K
Blood-based gene expression profiling in castrate-resistant prostate cancer
1Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, 9033 Wilshire Boulevard, Suite 300, Beverly Hills, CA, 90211, USA. mitchell.gross@usc.edu.
BMC Medicine
|September 15, 2015
Summary
Researchers identified a four-gene blood signature to predict prognosis in patients with castrate-resistant prostate cancer (CRPC). This blood-based marker may help personalize treatment strategies for this aggressive cancer.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Castrate-resistant prostate cancer (CRPC) is an aggressive form of prostate cancer with highly variable patient prognoses.
- Recent advancements have introduced new treatments, but predicting individual patient outcomes remains challenging.
Purpose of the Study:
- To identify and validate a blood-based gene expression signature for predicting prognosis in patients with CRPC.
- To explore the biological pathways involved in host-tumor interactions reflected in peripheral blood.
Main Methods:
- Discovery and validation of a four-gene expression model using whole-blood samples from three distinct clinical cohorts.
- Analysis incorporated biological pathways related to myeloid and lymphoid cells.
Main Results:
- A four-gene signature was identified and validated across independent cohorts.
- The signature shows potential for prognostic stratification in CRPC patients.
Conclusions:
- A novel four-gene blood-based signature demonstrates potential for prognostic assessment in CRPC.
- Further validation in larger datasets is needed to confirm its independent clinical significance and guide patient care.
